Tramadol


Curated chemical-gene interactions from CTD
Entrez gene IDGene symbolInteraction typeReference
114548 NLRP3 Increases expression PMID:39848458
1152 CKB Affects expression PMID:27317026; PMID:33645892
1158 CKM Increases expression PMID:33645892
142 PARP1 Increases expression PMID:39848458
148 ADRA1A Increases expression PMID:15464068
1586 CYP17A1 Decreases activity PMID:29100959
177 AGER Increases expression PMID:39848458
1813 DRD2 Increases expression PMID:15464068
1814 DRD3 Increases expression PMID:15464068
1965 EIF2S1 Increases expression PMID:39848458
249 ALPL Increases expression PMID:31618080
26762 HAVCR1 Increases expression PMID:39848458
2805 GOT1 Increases expression PMID:31618080
2875 GPT Increases activity PMID:28689766; PMID:39848458
2875 GPT Increases expression PMID:31618080
3356 HTR2A Increases activity PMID:18417104
3356 HTR2A Increases expression PMID:18417104
3553 IL1B Increases expression PMID:39848458
3939 LDHA Decreases expression PMID:27317026
468 ATF4 Increases expression PMID:39848458
4719 NDUFS1 Decreases expression PMID:27317026
4790 NFKB1 Increases expression PMID:39848458
4868 NPHS1 Decreases expression PMID:39848458
5165 PDK3 Increases expression PMID:27317026
5173 PDYN Decreases expression PMID:17401159
581 BAX Increases expression PMID:25550769; PMID:39848458; PMID:39848458
590 BCHE Decreases activity PMID:28689766
596 BCL2 Decreases expression PMID:39848458
598 BCL2L1 Decreases expression PMID:39848458
6647 SOD1 Decreases expression PMID:25550769; PMID:31618080
6648 SOD2 Decreases expression PMID:25550769
6696 SPP1 Increases expression PMID:33645892
7124 TNF Increases expression PMID:31618080; PMID:39848458; PMID:39848458
7137 TNNI3 Increases expression PMID:33645892
836 CASP3 Decreases activity PMID:27317026; PMID:28499616
836 CASP3 Increases expression PMID:31618080; PMID:39848458; PMID:39848458
847 CAT Decreases expression PMID:25550769; PMID:31618080
9451 EIF2AK3 Increases expression PMID:39848458

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.